

However, DP can contribute to Flutemetamol PET signal in regions with very high DP area coverage. Thus, Flutemetamol PET may correlate better with NIA-AA 2012 AD neuropathology criteria that incorporate both CERAD (NP) and Thal phases (all types of A β plaques).

IC-P-012 **ASSOCIATION OF RECENT MEMORY PERFORMANCE AND AMYLOID DEPOSITION IN AD CONTINUUM OF COGNITIVELY NORMAL ELDERLY SUBJECTS AND AMYLOID-POSITIVE MCI**



Takashi Kato¹, Kaori Iwata^{1,2}, Go Kizawa¹, Izumi Kuratsubo¹, Naohiko Fukaya¹, Masahiko Bundo¹, Yutaka Arahata¹, Kengo Ito¹, Akinori Nakamura¹, MULNIAD, ¹National Center for Geriatrics and Gerontology, Obu, Japan; ²Micron, Tokyo, Japan. Contact e-mail: tkato@ncgg.go.jp


Background: The purpose of this study was to investigate the decline of recent memory performance with amyloid PET and a surrogate maker of cognitive reserve in cognitively normal elderly people and amyloid positive patients with amnesic mild cognitive impairment (MCI). **Methods:** Subjects selected from in-house studies were 61 cognitively normal (CN) subjects (age: 69.8 ± 5.7 (60-82) y.o., years of school education (YSE): 12.2 ± 2.4 (9-18) years) and amyloid positive 17 patients with MCI (age: 74.6 ± 6.1 (60-82) y.o.; YSE: 11.4 ± 2.6 (8-16) years). They underwent a test of logical memory-II (LM-II) of Wechsler memory scale revised. Distribution volume ratio (DVR) image was calculated from dynamic PiB PET using simplified reference tissue mode 2. The DVR images spatially normalized using DARTEL method. Statistical analyses of the DVR images were performed with SPM8 for multiple regressions to assess the relationship with memory, age, and YSE. Correlation and regression analyses among regional DVR value, age, LM-II score and YSE were performed using SPSS. **Results:** Eleven out of 61 cases of CN were visually evaluated as amyloid-positive scan. LM-II score was 16.8 ± 6 (4-35) and 4.4 ± 4.8 (0-15) in CN and MCI, respectively. A SPM analysis of the group of CN demonstrated that LM-II score was inversely associated with DVR values in the bilateral localized medial temporal cortices ($p < 0.005$, ext > 50). In CN a significant correlation was observed between LM-II and YSE ($r > 0.5$, $p < 0.001$). Multiple regression analyses with LM-II as a dependent variable represented that statistically significant terms were YSE ($p < 0.001$) and an interaction term of YSE and regional DVR in the medial temporal lobe. In contrast, the combination group of CN and amyloid positive MCI showed an inverse association between DVR value and LM-II in wider areas such as anterior and posterior cingulate area, lateral temporal lobes, and basal forebrain in a SPM analysis ($p < 0.005$, ext > 50). **Conclusions:** The results suggest that, recent memory declines in association with amyloid deposition in the medial temporal lobe and cognitive reserve at cognitively normal stage, while recent memory performance goes down along with amyloid deposition spreading widely at the stage of cognitively normal to MCI in AD continuum.

IC-P-013 **AMYLOID ACCUMULATION WITHIN THE NEGATIVE RANGE IS LINKED TO MEMORY DECLINE IN COGNITIVELY NORMAL OLDER INDIVIDUALS**



Susan M. Landau¹, William J. Jagust^{1,2}, ¹University of California Berkeley, Berkeley, CA, USA; ²Lawrence Berkeley National Laboratory, Berkeley, CA, USA. Contact e-mail: slandau@berkeley.edu

Background: The earliest phase of amyloid accumulation, before deposition is widespread throughout cortex, is of great interest for understanding the etiology of Alzheimer's disease and for developing amyloid-modifying treatments. A critical question that has emerged is whether amyloid accumulation can be detected prior to amyloid positivity, and whether this accumulation is accompanied by any subtle changes in cognition. **Methods:** We identified 160 normal older individuals from the Alzheimer's Disease Neuroimaging Initiative who were negative on 18F-florbetapir PET based on global uptake in cortical summary regions. We contrasted the baseline florbetapir scans of subjects who subsequently increased or did not increase over 2 or 3 scans (2-4 years) of longitudinal florbetapir imaging in order to define a set of early accumulation regions at baseline. Then we determined whether amyloid accumulation within these early accumulation regions was related to concurrent memory change. **Results:** Early accumulation regions (regions elevated at baseline for subjects who subsequently increased) were located in bilateral precuneus, posterior cingulate, and superior parietal lobes. Within these regions, 103/160 (64%) of baseline-negative normals had positive florbetapir slopes. 17 subjects (4 APOE4+) converted to florbetapir positive status over 3.4 ± 1.0 yrs (3.1% per year). Negative normals who increased on florbetapir did not differ from nonincreasing subjects with respect to age, sex, education, ApoE4 status, baseline temporoparietal glucose metabolism, or hippocampal volume but they did have slightly higher baseline cortical florbetapir, indicating that accumulation was ongoing. Increasing florbetapir was associated with memory decline regardless of whether florbetapir change was assessed as a dichotomous ($p = 0.007$) or continuous ($p = 0.03$) variable. Finally, the effect was stronger for subjects with longer florbetapir followup (3 scans over 4.1 ± 0.3 yrs compared with 2 scans over 2.4 ± 0.8 yrs). **Conclusions:** Despite considerable variability in longitudinal amyloid and memory measurements in amyloid negative healthy older individuals, those with increasing



amyloid had poorer longitudinal memory performance than the nonincreasing group. These effects, though subtle, may represent the earliest consequences of amyloid deposition that are detectable prior to the onset of amyloid positivity and any clinically-relevant cognitive dysfunction.

IC-P-014

PREDICTION OF BETA-AMYLOID POSITIVITY IN MILD COGNITIVE IMPAIRMENT WITH DATA OBTAINED FROM ROUTINE MEMORY CLINIC PRACTICE



Jun Ho Lee¹, Min Soo Byun², Dahyun Yi², Young Min Choe³, Hyo Jung Choi¹, Hyewon Baek⁴, Bo Kyung Sohn^{5,6}, Hyun Jung Kim⁷, Jee Wook Kim⁸, Younghwa Lee¹, Seon Jin Yim⁹, Shin Gyeom Kim¹⁰, Dong Young Lee^{1,5}, ¹Seoul National University Hospital, Seoul, Republic of South Korea; ²Medical Research Center Seoul National University, Seoul, Republic of South Korea; ³Ulsan University Hospital, Ulsan, Republic of South Korea; ⁴Kyunggi Provincial Hospital for the Elderly, Yongin, Republic of South Korea; ⁵Seoul National University College of Medicine, Seoul, Republic of South Korea; ⁶SMG-SNU Boramae Medical Center, Seoul, Republic of South Korea; ⁷Changsan Convalescent Hospital, Changwon, Republic of South Korea; ⁸Hallym University Dongtan Sacred Hospital, Seoul, Republic of South Korea; ⁹Seoul National Hospital, Seoul, Republic of South Korea; ¹⁰Soon Chun Hyang University Bucheon Hospital, Bucheon, Republic of South Korea. Contact e-mail: kukulolv@naver.com

Background: Although recent advances in neuroimaging techniques have enabled the detection of in vivo Alzheimer's disease (AD) pathology in human, only a limited number of memory clinics are able to utilize it in clinical practice due to high cost and low accessibility. This study, therefore, aimed to develop prediction models for the beta-amyloid (A β) positivity on amyloid positron emission tomography (PET) in mild cognitive impairment (MCI) individuals with data that are routinely obtained in memory clinic setting. **Methods:** Sixty seven MCI patients were included in this study. All subjects received clinical and neuropsychological assessments, laboratory evaluations for blood sample, magnetic resonance imaging, and ¹¹C-labelled Pittsburgh Compound B (PiB) PET. For the development of A β positivity on PiB PET prediction models, all the variables were first categorized into four groups: clinical (C), neuropsychological (N), laboratory (L), and imaging (I) groups. In each group, the variables that showed significant or trend level association with A β positivity in univariate analyses were selected for further analyses. The selected variables of each group were combined sequentially in the prediction models, and logit values were calculated. Finally, with the logit values, the receiver operating characteristic (ROC) analyses were performed for each model to calculate the area under the curve (AUC). **Results:** For each group, following variables were selected: Total scores of geriatric depression scale, subjective memory complaint questionnaire, trait anxiety, blessed dementia scale-activities of daily living and history of hypertension for group C; raw scores of word list recall and recognition, and constructional recall for group N; triiodothyronine, high-density lipoprotein cholesterol, erythrocyte sedimentation rate, and APOE 4 positivity for group L; adjusted hippocampal volume for group I. In the ROC analyses, AUC for the prediction models were as follows: 0.793 for group C, 0.894 for combined group C+N, 0.956 for combined group C+N+L, and 0.944 for combined group C+N+L+I. **Conclusions:** The findings suggest that the systematic combinations of data obtained from routine clinical practice may be successfully used to predict A β positivity in MCI individuals.




Figure 1. The receiver operating characteristic (ROC) curves of each prediction model for amyloid positivity.

Table 1

Comparison of the area under the ROC curves of each prediction model

Model	AUC	SD	p	95% CI
Group C	0.793	0.055	<0.001	0.685-0.901
Group C+N	0.894	0.039	<0.001	0.818-0.969
Group C+N+L	0.956	0.023	<0.001	0.910-1.000
Group C+N+L+I	0.944	0.026	<0.001	0.593-0.996

Abbreviations: ROC, receiver operating characteristic; AUC, area under the curve; SD, standard deviation; CI, confidence interval.

IC-P-015

ASSOCIATION OF PAST AND CURRENT BODY MASS INDEX WITH BRAIN AMYLOID DEPOSITION AND NEURODEGENERATION IN COGNITIVELY NORMAL ELDERLY



Seung Hoon Lee¹, Min Soo Byun^{2,3}, Jun Ho Lee¹, Dahyun Yi^{1,2}, Bo Kyung Sohn⁴, Jun-Young Lee⁴, Young Min Choe⁵, Hyo Jung Choi^{1,3}, Hyewon Baek¹, Myeong-il Han⁶, Dong Young Lee^{1,3}, ¹Seoul National University Hospital, Seoul, Republic of South Korea; ²Medical Research Center Seoul National University, Seoul, Republic of South Korea; ³Seoul National University College of Medicine, Seoul, Republic of South Korea; ⁴SMG-SNU Boramae Medical Center, Seoul, Republic of South Korea; ⁵Ulsan University Hospital, Ulsan, Republic of South Korea; ⁶Maeumsarang Hospital, Wanju, Republic of South Korea. Contact e-mail: joamdosa@naver.com

Background: Both low and high body mass index(BMI) has been associated with cognitive impairment and Alzheimer disease(AD) dementia. Nevertheless, very little information is available for the association between BMI over life course and brain amyloid beta(A β) burden and AD-specific neurodegeneration. In this study, we examined the relationship of past and current BMI with in vivo cerebral A β deposition and AD-signature region cortical thickness in cognitively normal elderly population. **Methods:** Two-hundred twelve cognitively normal elderly subjects aged